8x8 Inc vs State Street SPDR S&P Biotech ETF — how do they compare? 8x8 Inc trades at $2 (market cap $309.09M), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, 8x8 Inc nearer its low. Which is the better fit depends on your goals.
| EGHT | XBI | |
|---|---|---|
Market Cap | $309.09M | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $2.76 | $164.28 |
52-Week Low | $1.59 | $86.92 |
Enterprise Value | $576.02M | — |
Signals from Pluang's Aura AI — not financial advice
EGHT trades at $2.01, down 10.27% today, with a bullish technical signal from moving averages. The company shows improving fundamentals with three consecutive quarterly EPS beats and projected profitability in 2026. Recent news highlights AI platform expansion and partner program enhancements driving growth.
The outlook appears constructive with analyst consensus target of $3.13 representing 56% upside potential. Key risks include high debt levels and negative retained earnings, while catalysts include continued AI adoption and revenue growth acceleration toward profitability.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Trailing returns across standard periods
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →